AZIS R. DABAS / STRATEGIC PERSPECTIVES
The whole health economy.
One strategic view.
Healthcare strategy has to explain how better population outcomes, sustainable care delivery and durable economics reinforce one another—and where they conflict. I examine the choices that connect them: allocation, incentives, orchestration, intelligence and control.
Six research-led analyses · September 2026
Original strategic positions, primary-source evidence and explicit decision models.
Growth becomes durable when demand, delivery capability and financial capacity develop together.
RESEARCH / THE FULL HEALTHCARE ECONOMY
Evidence that changes the operating decision.
87 articles connect care delivery, pharmacy, population health, payer economics, organizational design and capital. Nine focused research briefs examine methods and limitations; analytical exhibits expose the arithmetic behind the strategy.
SIX NEW THESIS ESSAYS / SEPTEMBER 2026
Where evidence meets
an operating choice.
My original analysis across six care settings. Each essay identifies the study design, its limits, a concrete business use case and the evidence that would change the decision.
Cardiometabolic health
Obesity Pharmacotherapy Is Becoming a Continuity Business
Treat renewal, access and clinically supervised transitions as a funded service—with patient choice and total costs in view.
Evidence: Nature Medicine ·
Kidney care
Kidney Prevention Belongs in the Capital Plan Before the Next Dialysis Expansion
Evaluate prevention alongside dialysis expansion, with clear limits on what biomarkers can tell a capital committee.
Evidence: JAMA Cardiology ·
Women's health
The Postpartum Handoff Is a Business Model: Pay for Continuity Beyond Delivery
Fund the handoff from maternity services into continuing care, and test the response capacity behind remote monitoring.
Evidence: JAMA Network Open ·
Aging and dementia
Dementia Care Needs a Capacity Contract: Finance the Household, Not Just the Referral
Purchase reliable household and workforce support, while separating caregiver benefit from assumed claims savings.
Evidence: JAMA Internal Medicine ·
Oncology and precision diagnostics
Precision Oncology’s Next Investment Is the Pathway Between the Report and Treatment
Follow the losses between genomic testing, interpretation and feasible treatment before expanding assay capacity.
Evidence: Asia-Pacific Journal of Clinical Oncology ·
Acute care and community delivery
Hospital at Home Must Buy Community Capacity Before It Can Release Hospital Capacity
Price community delivery, household support and released hospital capacity as separate parts of the operating case.
Evidence: JAMA Network Open ·
THE CURRENT RESEARCH / AN ORIGINAL SYNTHESIS
What the evidence changes
about the strategy.
Recent scholarship from Harvard, Brown, Stanford, Cornell, Duke and UCLA—examined through integration, population health, AI, incentives and capital allocation.
Read my September 2026 synthesis ↗THE CONNECTED LAYER / AN INTERACTIVE OPERATING FRAMEWORK
One person.
16 connected domains.
Explore the decisions linking pharmacy, behavioral health, social and public health, wireless sensing, payer-provider economics and AI. Test the capacity and cost of following through.
Explore whole-care systems ↗PUBLIC HEALTH & POPULATION STRATEGY
Optimize for population benefit, not the visible cost curve.
A population strategy must reconcile unmet need, intervention effectiveness, delivery capacity and the distribution of benefit—including people whose needs are poorly represented in claims.
Read the analysis ↗VALUE-BASED CARE & RISK ECONOMICS
A shared-savings payment is not the same as value created.
Underwrite patient outcomes, provider economics and payer spending separately. Then reconcile the contract, the counterfactual and the cash required to sustain care.
Read the analysis ↗WHOLE-CARE ORCHESTRATION & AI
Own the unresolved handoff.
Whole-care orchestration connects clinical care, behavioral health, pharmacy, social support and financing around one person—with explicit responsibility when the next step cannot happen.
Read the analysis ↗AI STRATEGY & ENTERPRISE ECONOMICS
AI creates capacity. Strategy determines its value.
The enterprise case begins after a task gets faster: what changes in care, whose work remains, which costs disappear and who retains the economic benefit.
Read the analysis ↗CAPITAL ALLOCATION & DOWNSIDE
Capital should buy evidence before it buys permanence.
An investment thesis becomes useful when it specifies which uncertainty to resolve, what commitment to make now and what evidence earns the next allocation.
Read the analysis ↗MARKET STRUCTURE & STRATEGIC POSITION
Who creates value—and who gets to keep it?
Healthcare strategy begins with the distribution of power: who controls access, who sets the economic terms, who bears the risk and who can credibly choose another path.
Read the analysis ↗THE FINANCIAL STRUCTURE
Examine the equations behind the argument.
Payer underwriting and claims reserves. Hospital acuity and staffed capacity. Value-based care settlement. Returns on invested capital. Four interactive scenarios expose the assumptions and the tradeoffs.
Open the executive economics workbench ↗THE EXECUTIVE AGENDA
Make the tradeoffs visible.
My starting point is the decision that cannot be delegated to a dashboard: what to prioritize, what to fund, what to own and what evidence would change course.
| Leadership choice | The economic question | The health-system test |
|---|---|---|
| Population | Where does the next dollar have a credible path to benefit? | Who is missing, which needs are unmet, and what access floor must hold? |
| Care model | Which service can change the outcome at a sustainable cost? | Can the person reach it, use it and complete the next step? |
| Risk contract | Who funds the work, receives the return and absorbs the downside? | Do quality, access and clinical incentives remain aligned? |
| AI and data | What value survives adoption, review, exceptions and operating cost? | Who is authorized to act, correct the record and stop the system? |
| Enterprise boundary | Which capability should we own, contract or access through a partner? | Does the structure improve care and preserve practical choice? |
| Capital | What evidence earns the next commitment? | Can the organization sustain the service through a downside scenario? |
THE CONNECTION TO MY WORK
Strategic judgment, under operating conditions.
Founder P&L ownership, kidney-care networks, claims intelligence and behavioral-health growth provide the operating context. The analyses above extend that perspective into current questions facing payers, providers, healthtech companies and investors.
Explore the operating cases ↗CONTINUE THE EXECUTIVE PERSPECTIVE